Vapor,
I agree funding issues are off the table for the time being, but I would not rule out future raises before WP's anticipated commercialisation in 2025.
Despite AVR having a potential world class product, it's still a biotech junior without an income to support its progress towards profitability.
Nevertheless, AVR will remain my biggest portfolio (54%) holding, such is my faith in the product and company.
Ann: Capital Raise, page-7
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |